ImmunoCellular Therapeutics is a clinical-stage company focused on the development of immune-based therapies for treating brain and other cancers. The company has commenced a Phase II trial of its lead product candidate ICT-107, which is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular Therapeutics is based in Los Angeles, Calif. For more information, visit the company’s Web site at www.imuc.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: